14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Jan 17, 2024 $241.92 $245.00 $235.25 $239.96 319 946
Jan 16, 2024 $232.19 $245.17 $230.27 $243.92 350 486
Jan 12, 2024 $240.00 $244.12 $234.87 $235.80 240 011
Jan 11, 2024 $231.94 $243.00 $227.12 $240.31 323 257
Jan 10, 2024 $240.28 $244.66 $232.01 $236.74 242 855
Jan 09, 2024 $225.85 $238.42 $225.85 $237.95 338 403
Jan 08, 2024 $219.11 $231.09 $216.74 $230.80 296 091
Jan 05, 2024 $217.55 $221.67 $214.21 $220.28 167 485
Jan 04, 2024 $215.59 $224.34 $208.99 $218.21 439 116
Jan 03, 2024 $226.40 $229.00 $210.96 $211.94 390 512
Jan 02, 2024 $229.65 $235.37 $225.92 $226.86 252 423
Dec 29, 2023 $233.77 $234.92 $228.78 $231.38 310 739
Dec 28, 2023 $236.17 $240.54 $231.54 $233.99 316 692
Dec 27, 2023 $239.73 $241.79 $234.68 $236.75 203 585
Dec 26, 2023 $235.74 $241.07 $233.47 $236.32 300 025
Dec 22, 2023 $228.26 $242.76 $227.64 $235.07 467 888
Dec 21, 2023 $225.01 $226.58 $219.84 $222.30 221 331
Dec 20, 2023 $229.80 $232.13 $220.61 $221.04 332 948
Dec 19, 2023 $232.73 $235.09 $227.11 $230.88 305 242
Dec 18, 2023 $235.27 $237.12 $225.64 $230.00 232 036
Dec 15, 2023 $236.53 $245.31 $229.41 $237.13 631 055
Dec 14, 2023 $231.04 $235.99 $224.38 $233.02 394 595
Dec 13, 2023 $222.18 $227.51 $216.21 $227.33 463 809
Dec 12, 2023 $210.09 $222.85 $204.60 $222.18 378 648
Dec 11, 2023 $211.27 $212.97 $202.97 $210.43 381 655
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT